- Home
- ICCC vs CTSO Comparison
ICCC vs CTSO Comparison
Compare ICCC & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCC
- CTSO
- Stock Information
- Founded
- ICCC 1982
- CTSO 1997
- Country
- ICCC United States
- CTSO United States
- Employees
- ICCC N/A
- CTSO N/A
- Industry
- ICCC Biotechnology: Pharmaceutical Preparations
- CTSO Medical/Dental Instruments
- Sector
- ICCC Health Care
- CTSO Health Care
- Exchange
- ICCC Nasdaq
- CTSO Nasdaq
- Market Cap
- ICCC 61.3M
- CTSO 52.6M
- IPO Year
- ICCC 1987
- CTSO N/A
- Fundamental
- Price
- ICCC $5.90
- CTSO $1.18
- Analyst Decision
- ICCC
- CTSO Buy
- Analyst Count
- ICCC 0
- CTSO 2
- Target Price
- ICCC N/A
- CTSO $5.50
- AVG Volume (30 Days)
- ICCC 27.4K
- CTSO 99.9K
- Earning Date
- ICCC 08-12-2025
- CTSO 08-12-2025
- Dividend Yield
- ICCC N/A
- CTSO N/A
- EPS Growth
- ICCC N/A
- CTSO N/A
- EPS
- ICCC N/A
- CTSO N/A
- Revenue
- ICCC $27,302,766.00
- CTSO $35,332,238.00
- Revenue This Year
- ICCC N/A
- CTSO $18.34
- Revenue Next Year
- ICCC N/A
- CTSO $19.82
- P/E Ratio
- ICCC N/A
- CTSO N/A
- Revenue Growth
- ICCC 28.29
- CTSO 15.37
- 52 Week Low
- ICCC $3.34
- CTSO $0.70
- 52 Week High
- ICCC $7.60
- CTSO $1.61
- Technical
- Relative Strength Index (RSI)
- ICCC 50.09
- CTSO 67.21
- Support Level
- ICCC $6.14
- CTSO $1.03
- Resistance Level
- ICCC $6.58
- CTSO $1.29
- Average True Range (ATR)
- ICCC 0.25
- CTSO 0.09
- MACD
- ICCC -0.07
- CTSO 0.02
- Stochastic Oscillator
- ICCC 1.15
- CTSO 75.45
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.